RESUMEN
A recent phase 3 trial of prucalopride in children with functional constipation (SPD555-303 ClinicalTrials.gov Identifier: NCT01330381) reported negative efficacy results. Here, we developed a population pharmacokinetic (PK) model of prucalopride in children to assess prucalopride exposure in SPD555-303. An initial population PK model in children was developed based on sampled single-dose data from a phase 1 study (PRU-USA-12). This model was subsequently updated with sampled data from SPD555-303 and used to simulate plasma concentration-time profiles for children aged 6 months to 18 years who were treated once daily with prucalopride 0.02, 0.04, or 0.06 mg kg-1 (maximum dose, 2 mg). Simulated PK profiles were compared with those of adults at the recommended dose of 2 mg once daily. Data were available from 38 patients (median age, 8.5 years) in PRU-USA-12 and 137 patients (median age, 7.9 years) in SPD555-303. Mean (range) area under the plasma concentration-time curve (AUC) at steady state was 62.3 (40.5-82.7) ng mL-1 h (dose, 0.03 mg kg-1) in PRU-USA-12 and 100.3 (22.7-286.0) ng mL-1 h (dose, 0.04 mg kg-1; maximum, 2 mg) in SPD555-303. Prucalopride 0.04 mg kg-1 once daily in children produced similar maximum plasma concentrations and approximately 10% lower AUC compared with adults receiving 2 mg once daily. This population PK analysis indicates that the PK profile of prucalopride in children in SPD555-303 was similar to that observed in adults. The negative efficacy results of SPD555-303 cannot be explained by differences in prucalopride exposure between children and adults.
RESUMEN
BACKGROUND: Prucalopride, a selective, high-affinity 5-hydroxytryptamine 4 receptor agonist, stimulates gastrointestinal and colonic motility and alleviates common symptoms of chronic constipation (CC) in adults. The relative efficacy by gender has not been evaluated. AIM: To evaluate the global efficacy and safety of prucalopride 2 mg daily in men and women with CC using data from six large, randomized, controlled clinical trials. METHODS: Data were combined from six phase 3 and 4, double-blind, randomized, placebo-controlled, parallel-group trials. The primary efficacy endpoint was the percentage of patients with a mean of ≥3 spontaneous complete bowel movements (SCBMs) per week over 12 weeks of treatment. Safety was assessed throughout all the trials. RESULTS: Overall, 2484 patients (597 men; 1887 women; prucalopride, 1237; placebo, 1247) were included in the integrated efficacy analysis and 2552 patients were included in the integrated safety analysis. Significantly more patients achieved a mean of ≥3 SCBMs/week over the 12 weeks of treatment in the prucalopride group (27.8 %) than in the placebo group [13.2 %, OR 2.68 (95 % CI 2.16, 3.33), p < 0.001]. Prucalopride had a favorable safety and tolerability profile. Efficacy and safety outcomes were not significantly different between men and women. CONCLUSION: The integrated analysis demonstrates the efficacy and safety of prucalopride in the treatment of CC in men and women.
Asunto(s)
Benzofuranos/uso terapéutico , Estreñimiento/tratamiento farmacológico , Agonistas del Receptor de Serotonina 5-HT4/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Enfermedad Crónica , Ensayos Clínicos Fase III como Asunto , Ensayos Clínicos Fase IV como Asunto , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento , Adulto JovenRESUMEN
PURPOSE: To describe the nature, extent, and impact of spasticity; determine factors that are perceived to influence its severity; and examine the relationship between time since diagnosis and impact of spasticity on daily activities in people with stroke and multiple sclerosis (MS) who are receiving botulinum toxin injection treatments. METHODS: After a cross-sectional telephone survey, descriptive statistics and correlations were analyzed separately for the stroke and MS groups. RESULTS: A total of 29 people with stroke and 10 with MS were surveyed. Both groups perceived increased spasticity with outdoor cold (69% stroke, 60% MS), muscle fatigue (59% stroke, 80% MS), and mental stress (59% stroke, 90% MS). No statistically significant correlations were found between time since diagnosis and perceived impact of spasticity on function in the stroke (r=0.07, p=0.37) or MS (r=0.16, p=0.33) groups. The MS group experienced bilateral and more severe perception of spasticity in the legs than the stroke group and identified more factors as worsening their spasticity (p<0.05). Severity of leg (but not arm) spasticity was significantly correlated with severity of impact of the following factors in the MS group only: lying on the back (r=0.70, p<0.05), outdoor heat (r=0.61, p<0.05), and morning (r=0.59, p<0.05). CONCLUSION: Intrinsic and extrinsic triggers can influence the perception of spasticity differently depending on individual factors, severity, location (arm vs. leg), and distribution of spasticity (unilateral vs. bilateral). Clinicians can use the findings to better understand, educate, and treat people with stroke and MS.
Objet : Décrire la nature, l'étendue et l'effet de la spasticité; déterminer les facteurs qui, croit-on, ont un effet sur sa gravité; examiner le lien entre le temps écoulé depuis le diagnostic et l'effet de la spasticité sur les activités quotidiennes chez des personnes qui avaient subi un accident vasculaire cérébral et chez d'autres qui avaient la sclérose en plaques (SP) et qui reçoivent des traitements par injection de toxine botulique. Méthodes : À la suite d'un sondage téléphonique transversal, on a analysé des statistiques descriptives et des corrélations séparément pour les patients qui avaient subi un accident vasculaire cérébral et ceux qui avaient la SP. Résultats : Au total, on a sondé 29 personnes victimes d'un accident vasculaire cérébral et 10 autres qui avaient la SP. Les deux groupes ont perçu une spasticité accrue par temps froid à l'extérieur (69 % accident vasculaire cérébral, 60 % SP), de la fatigue musculaire (59 % accident vasculaire cérébral, 80 % SP) et du stress mental (59 % accident vasculaire cérébral, 90 % SP). On n'a constaté aucune corrélation statistiquement significative entre le temps écoulé depuis le diagnostic et l'effet perçu de la spasticité sur le fonctionnement chez les groupes de patients qui avaient subi un accident vasculaire cérébral (r=0,07, p=0,37) ou qui avaient la SP (r=0,16, p=0,33). Les personnes qui avaient la SP avaient une perception bilatérale et plus grave de la spasticité dans les jambes que celles qui avaient subi un accident vasculaire cérébral et elles ont indiqué un plus grand nombre de facteurs qui aggravaient leur spasticité (p<0,05). On a établi une corrélation significative entre la gravité de la spasticité des jambes (mais non des bras) et la gravité de l'effet des facteurs suivants chez les personnes qui avaient la SP seulement: position couchée sur le dos (r=0,70, p<0,05), chaleur à l'extérieur (r=0,61, p<0,05) et l'avant-midi (r=0,59, p<0,05). Conclusion : Des facteurs déclencheurs intrinsèques et extrinsèques peuvent avoir un effet sur la perception de la spasticité qui diffère selon les facteurs individuels, la gravité, l'endroit atteint (bras ou jambe) et l'étendue de la spasticité (unilatérale ou bilatérale). Les cliniciens peuvent utiliser les constatations pour mieux comprendre, informer et traiter les personnes qui ont subi un accident vasculaire cérébral et celles qui ont la SP.
RESUMEN
OBJECTIVES: Prucalopride is effective at alleviating symptoms of chronic constipation in women. The aim of this study was to assess the efficacy of 12 weeks of prucalopride treatment compared with placebo in men with chronic constipation. METHODS: This was a multicenter, stratified, randomized, parallel-group, double-blind, placebo-controlled, phase 3 study (ClinicalTrials.gov identifier: NCT01147926). The primary end point was the proportion of patients with a mean of three or more spontaneous complete bowel movements (SCBMs) per week across the treatment period. Efficacy end points were assessed using daily electronic diaries, global assessment of the severity of constipation and efficacy of treatment, and Patient Assessment of Constipation-Symptoms (PAC-SYM) and Patient Assessment of Constipation-Quality of Life (PAC-QOL) questionnaires. RESULTS: In total, 374 patients were enrolled in the study. Significantly more patients achieved a mean of three or more SCBMs per week in the prucalopride group (37.9%) than in the placebo group (17.7%, P<0.0001). The proportion of patients rating their constipation treatment as "quite a bit" to "extremely" effective at the final on-treatment visit was 46.7 and 30.4% in the prucalopride and placebo groups, respectively. The difference between treatment groups was statistically significant (P<0.0001). The proportion of patients with an improvement of at least 1 point in PAC-QOL satisfaction subscale score was 52.7 and 38.8% in the prucalopride and placebo groups, respectively (P=0.0035). Prucalopride had a good safety profile and was well tolerated. CONCLUSIONS: Prucalopride is effective, has a good safety profile, and is well tolerated for the treatment of men with chronic constipation.
Asunto(s)
Benzofuranos/uso terapéutico , Agonistas del Receptor de Serotonina 5-HT4/uso terapéutico , Dolor Abdominal/inducido químicamente , Adulto , Anciano , Benzofuranos/efectos adversos , Enfermedad Crónica , Defecación , Diarrea/inducido químicamente , Método Doble Ciego , Cefalea/inducido químicamente , Humanos , Masculino , Registros Médicos , Persona de Mediana Edad , Náusea/inducido químicamente , Calidad de Vida , Agonistas del Receptor de Serotonina 5-HT4/efectos adversos , Índice de Severidad de la Enfermedad , Encuestas y CuestionariosRESUMEN
Bazedoxifene (BZA) is a selective estrogen receptor modulator that has been shown to prevent and treat postmenopausal osteoporosis. Hip structure analysis (HSA) can be used to extract bone structural properties related to strength from hip bone mineral density (BMD) scans. This exploratory analysis used HSA to evaluate changes in hip structural geometry in postmenopausal women enrolled in a phase 3 osteoporosis treatment study who were treated with BZA 20mg or placebo for 2 years. This analysis cohort included women at increased fracture risk based on known skeletal risk factors (n = 521); 1 or more moderate or severe fractures or 2 or more mild vertebral fractures and/or femoral neck BMD T-score ≤ -3.0 at baseline combined with additional women from the overall study population (n = 475); a subgroup analysis included just those women at increased fracture risk. HSA was applied to duplicate hip dual-energy X-ray absorptiometry (DXA) scans acquired at screening and 24 months. Percent change from baseline was evaluated using an analysis of covariance for BMD and geometric parameters including section modulus (SM), cross-sectional area (CSA), outer diameter (OD), and buckling ratio (BR). In all regions, BZA was associated with increased BMD and improvements in hip structural geometry. In the narrow neck, BZA 20mg significantly increased SM, CSA, OD, and BMD compared with placebo (P < 0.05 for all). In the intertrochanter region, BZA 20mg significantly increased CSA and BMD and decreased BR compared with placebo (P < 0.05 for all). Other than BMD (P < 0.05), effects of BZA 20mg at the shaft did not reach statistical significance. Similar trends toward improvement in structural geometry with BZA 20mg were observed in all three regions of the hip for the subgroup of women at increased fracture risk. Overall, BZA was associated with geometry-related improvements in bone strength with regard to resistance to bending and compressive forces and to local buckling. These improvements were evident at common fracture locations such as the femoral neck and intertrochanter regions, and are consistent with the significant treatment effect reported for BZA on nonvertebral fractures in higher-risk postmenopausal women with osteoporosis.
Asunto(s)
Conservadores de la Densidad Ósea/uso terapéutico , Huesos/efectos de los fármacos , Indoles/uso terapéutico , Osteoporosis Posmenopáusica/tratamiento farmacológico , Absorciometría de Fotón , Anciano , Densidad Ósea , Conservadores de la Densidad Ósea/farmacología , Huesos/fisiopatología , Estudios de Cohortes , Femenino , Humanos , Indoles/farmacología , Persona de Mediana Edad , Osteoporosis Posmenopáusica/diagnóstico por imagen , PlacebosRESUMEN
OBJECTIVE: In a 3-year randomized, double-blind, osteoporosis treatment study (N = 7,492), bazedoxifene 20 mg and bazedoxifene 40 mg significantly (P < 0.05) reduced the risk of new vertebral fractures by 42% and 37%, respectively, compared with placebo in postmenopausal women with osteoporosis. This study evaluated the long-term (7-y) efficacy and safety of bazedoxifene in generally healthy postmenopausal women with osteoporosis. METHODS: This was a second 2-year extension of the 3-year multicenter outpatient core study. During extension I (years 4-5), women receiving bazedoxifene 40 mg transitioned to bazedoxifene 20 mg. In extension II (years 6-7; N = 1,530), all bazedoxifene-treated women continued bazedoxifene 20 mg. Main outcome measures included year 7 endpoints: incidences of new vertebral and nonvertebral fractures, bone mineral density changes, and safety assessments. RESULTS: At 7 years, the cumulative incidences of new vertebral fractures were significantly lower in the bazedoxifene (6.4%) and bazedoxifene 20 mg (7.6%) groups than in the placebo group (9.9%); the relative risk reductions were 36.5% and 30.4%, respectively (both P < 0.001). Bazedoxifene had no effect on the overall incidence of nonvertebral fractures (bazedoxifene, 11.2%; bazedoxifene 20 mg, 12.0%; placebo, 10.8%). The mean changes from baseline in lumbar spine bone mineral density were 2.95%, 2.73%, and 2.19%, respectively. Seven-year decreases in total hip bone mineral density were significantly smaller in the bazedoxifene (-1.15%) and bazedoxifene 20 mg (-1.19%) groups than in the placebo group (-2.53%; P ≤ 0.002). Bazedoxifene showed a favorable safety/tolerability profile across 7 years, with similar adverse events, serious adverse events, and study discontinuations in all groups. CONCLUSIONS: Efficacy and safety of bazedoxifene are sustained across 7 years in postmenopausal women with osteoporosis.
Asunto(s)
Conservadores de la Densidad Ósea/administración & dosificación , Densidad Ósea/efectos de los fármacos , Fracturas Óseas/epidemiología , Indoles/administración & dosificación , Osteoporosis Posmenopáusica/tratamiento farmacológico , Anciano , Conservadores de la Densidad Ósea/efectos adversos , Método Doble Ciego , Femenino , Fracturas Óseas/etiología , Humanos , Incidencia , Indoles/efectos adversos , Vértebras Lumbares/efectos de los fármacos , Persona de Mediana Edad , Osteoporosis Posmenopáusica/complicaciones , Huesos Pélvicos/efectos de los fármacos , Posmenopausia , Tiempo , Resultado del TratamientoRESUMEN
BACKGROUND & AIMS: Prucalopride is a selective, high-affinity agonist of the 5-hydroxytryptamine (serotonin) receptor 4 that enhances motility in the gastrointestinal tract. We performed a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of prucalopride in children (6 months to 18 years old) with functional constipation. METHODS: Children with functional constipation, based on the Rome III criteria, were given prucalopride (children ≤ 50 kg were given a 0.04 mg/kg oral solution; children >50 kg were given a 2-mg tablet) or placebo once daily for 8 weeks. The primary efficacy end point was the proportion of children with toileting skills who had a mean of ≥ 3 spontaneous bowel movements/week and ≤ 1 episode of fecal incontinence/2 weeks, from study weeks 5-8 (responders). Adverse events, clinical laboratory values, and electrocardiograms were monitored. RESULTS: Efficacy and safety were assessed in 213 children (106 prucalopride, 107 placebo). Twenty-five percent were younger than 4 years old, 50% were 4-11 years old, and 25% were 12-18 years old; 55.4% were girls. At screening, 62.3% of patients in the prucalopride group and 55.1% in the placebo group had a history of fecal incontinence; 60.4% and 55.1% in the prucalopride and placebo groups, respectively, had a mean of ≤ 1 spontaneous bowel movements/week. The proportion of responders was similar between groups (prucalopride, 17.0% and placebo, 17.8%). There were no statistically significant differences in the primary efficacy end point when patients were stratified by sex, age group, or country. The incidence of treatment-emergent adverse events was similar in the prucalopride (69.8%) and placebo (60.7%) groups. CONCLUSIONS: Prucalopride, although generally well tolerated, was not more effective than placebo in children with functional constipation. ClinicalTrials.gov Number: NCT01330381.
Asunto(s)
Benzofuranos/administración & dosificación , Estreñimiento/tratamiento farmacológico , Defecación/efectos de los fármacos , Impactación Fecal/tratamiento farmacológico , Agonistas del Receptor de Serotonina 5-HT4/administración & dosificación , Adolescente , Benzofuranos/efectos adversos , Niño , Preescolar , Método Doble Ciego , Femenino , Humanos , Lactante , Masculino , Agonistas del Receptor de Serotonina 5-HT4/efectos adversos , Insuficiencia del TratamientoRESUMEN
OBJECTIVE: To evaluate the clinical safety of bazedoxifene (BZA) on the reproductive tract in postmenopausal women with osteoporosis over 7 years. STUDY DESIGN: This was a second, blinded, 2-year extension of a 3-year, randomized, double-blind, placebo (PBO)- and active-controlled phase 3 trial. In the core study, subjects were randomized to receive BZA 20 or 40mg, raloxifene 60mg, or PBO. During years 4-5, the raloxifene arm was discontinued and subjects receiving BZA 40mg were transitioned to BZA 20mg. Subjects continued to receive BZA 20mg or PBO during years 6-7. MAIN OUTCOME MEASURES: The primary endpoint was the incidence of new vertebral fractures at 7 years (reported separately). Reproductive tract safety findings at 7 years are reported here. Endometrial thickness was assessed by transvaginal ultrasonography for subjects in the endometrial safety substudy. Adverse events (AEs) were recorded throughout the study. RESULTS: At 7 years, the adjusted mean (±standard error) change in endometrial thickness was similar with BZA and PBO (-0.11 ± 0.21 and 0.07 ± 0.32 mm, respectively). The incidence of endometrial hyperplasia was low (0.1% for both groups). BZA showed significantly lower rates than PBO of endometrial carcinoma (0.1% vs. 0.4%; P=0.020) and vaginitis (6.1% vs. 7.6%; P=0.035). There were more cases of ovarian carcinoma with BZA (n=4 [0.1%]) than PBO (n=0); the difference was not statistically significant. Rates of breast-related and other gynecologic AEs were similar among groups. CONCLUSIONS: BZA was associated with a favorable reproductive safety profile in postmenopausal women with osteoporosis over 7 years.
Asunto(s)
Conservadores de la Densidad Ósea/efectos adversos , Endometrio/efectos de los fármacos , Indoles/efectos adversos , Osteoporosis Posmenopáusica/tratamiento farmacológico , Moduladores Selectivos de los Receptores de Estrógeno/efectos adversos , Anciano , Conservadores de la Densidad Ósea/uso terapéutico , Carcinoma Epitelial de Ovario , Método Doble Ciego , Hiperplasia Endometrial/epidemiología , Neoplasias Endometriales/epidemiología , Endometrio/diagnóstico por imagen , Femenino , Humanos , Incidencia , Indoles/uso terapéutico , Persona de Mediana Edad , Neoplasias Glandulares y Epiteliales/inducido químicamente , Neoplasias Glandulares y Epiteliales/epidemiología , Neoplasias Ováricas/inducido químicamente , Neoplasias Ováricas/epidemiología , Posmenopausia , Moduladores Selectivos de los Receptores de Estrógeno/uso terapéutico , Fracturas de la Columna Vertebral/prevención & control , Ultrasonografía , Vaginitis/epidemiologíaRESUMEN
Neotropical monkeys of the genera Cacajao, Chiropotes, and Pithecia (Pitheciidae) are considered to be highly arboreal, spending most of their time feeding and traveling in the upper canopy. Until now, the use of terrestrial substrates has not been analyzed in detail in this group. Here, we review the frequency of terrestrial use among pitheciin taxa to determine the ecological and social conditions that might lead to such behavior. We collated published and unpublished data from 14 taxa in the three genera. Data were gleaned from 53 published studies (including five on multiple pitheciin genera) and personal communications of unpublished data distributed across 31 localities. Terrestrial activity was reported in 61% of Pithecia field studies (11 of 18), in 34% of Chiropotes studies (10 of 29), and 36% of Cacajao studies (4 of 11). Within Pithecia, terrestrial behavior was more frequently reported in smaller species (e.g. P. pithecia) that are vertical clingers and leapers and make extensive use of the understory than in in the larger bodied canopy dwellers of the western Amazon (e.g. P. irrorata). Terrestrial behavior in Pithecia also occurred more frequently and lasted longer than in Cacajao or Chiropotes. An apparent association was found between flooded habitats and terrestrial activity and there is evidence of the development of a "local pattern" of terrestrial use in some populations. Seasonal fruit availability also may stimulate terrestrial behavior. Individuals also descended to the ground when visiting mineral licks, escaping predators, and responding to accidents such as a dropped infant. Overall, the results of this review emphasize that terrestrial use is rare among the pitheciins in general and is usually associated with the exploitation of specific resources or habitat types.
Asunto(s)
Conducta Animal , Ecosistema , Pitheciidae , Animales , Femenino , Masculino , Conducta Predatoria , Estaciones del Año , América del SurRESUMEN
BACKGROUND: We report the safety findings from a 3-year phase 3 study (NCT00205777) of bazedoxifene, a novel selective estrogen receptor modulator under development for the prevention and treatment of postmenopausal osteoporosis. METHODS: Healthy postmenopausal osteoporotic women (N = 7,492; mean age, 66.4 years) were randomized to daily doses of bazedoxifene 20 or 40 mg, raloxifene 60 mg, or placebo for 3 years. Safety and tolerability were assessed by adverse event (AE) reporting and routine physical, gynecologic, and breast examination. RESULTS: Overall, the incidence of AEs, serious AEs, and discontinuations due to AEs in the bazedoxifene groups was not different from that seen in the placebo group. The incidence of hot flushes and leg cramps was higher with bazedoxifene or raloxifene compared with placebo. The rates of cardiac disorders and cerebrovascular events were low and evenly distributed among groups. Venous thromboembolic events, primarily deep vein thromboses, were more frequently reported in the active treatment groups compared with the placebo group; rates were similar with bazedoxifene and raloxifene. Bazedoxifene showed a neutral effect on the breast and an excellent endometrial safety profile. The incidence of fibrocystic breast disease was lower with bazedoxifene 20 and 40 mg versus raloxifene or placebo. Reductions in total and low-density lipoprotein levels and increases in high-density lipoprotein levels were seen with bazedoxifene versus placebo; similar results were seen with raloxifene. Triglyceride levels were similar among groups. CONCLUSION: Bazedoxifene showed a favorable safety and tolerability profile in women with postmenopausal osteoporosis. TRIAL REGISTRATION NUMBER: NCT00205777; Trial registration date: September 16, 2005.
Asunto(s)
Conservadores de la Densidad Ósea/efectos adversos , Indoles/administración & dosificación , Indoles/efectos adversos , Osteoporosis Posmenopáusica/tratamiento farmacológico , Moduladores Selectivos de los Receptores de Estrógeno/efectos adversos , Anciano , Anciano de 80 o más Años , Conservadores de la Densidad Ósea/administración & dosificación , Método Doble Ciego , Femenino , Humanos , Persona de Mediana Edad , Osteoporosis Posmenopáusica/fisiopatología , Placebos , Clorhidrato de Raloxifeno/administración & dosificación , Clorhidrato de Raloxifeno/efectos adversos , Moduladores Selectivos de los Receptores de Estrógeno/administración & dosificación , Resultado del TratamientoRESUMEN
Antiretroviral therapy during pregnancy in HIV-infected women has dramatically reduced the rate of mother to child HIV transmission in the United States. National guidelines strongly recommend universal HIV testing of all pregnant women with repeat screening in the third-trimester in high-risk populations. To determine patient attitudes towards third-trimester rescreening, a convenience sample was recruited during routine prenatal visits at an urban clinic and participants were surveyed to determine attitudes about HIV third-trimester retesting, acceptability of the rapid HIV testing, condom use, and knowledge of partner's HIV status during pregnancy. Participants were offered a third-trimester rapid HIV retest with the option to decline the test. Eighty pregnant women participated; 95% agreed to be retested with a rapid HIV test, 100% received immediate HIV results, and 91% reported that the rapid test was less stressful than conventional testing. There were no seroconversions. Although 35% did not know their partner's HIV status, 57% of these women reported never using condoms during pregnancy. There was a significant association between reported stage of behavior change and reported likelihood of using condoms. We found that rescreening with the rapid HIV test in the third trimester of pregnancy was well accepted and is important to prevent perinatal HIV transmission.
Asunto(s)
Condones/estadística & datos numéricos , Infecciones por VIH/diagnóstico , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Complicaciones Infecciosas del Embarazo/diagnóstico , Tercer Trimestre del Embarazo , Adolescente , Adulto , Actitud Frente a la Salud , Femenino , Infecciones por VIH/transmisión , Seropositividad para VIH/diagnóstico , Seropositividad para VIH/transmisión , Conductas Relacionadas con la Salud , Humanos , Persona de Mediana Edad , Embarazo , Factores de Tiempo , Adulto JovenRESUMEN
OBJECTIVE: The aim of this study was to examine the endometrial, ovarian, and breast safety of bazedoxifene, a novel selective estrogen-receptor modulator, in postmenopausal women at risk for osteoporosis. METHODS: Healthy postmenopausal women (N = 1,583; mean age, 57.6 y) with lumbar spine or femoral neck bone mineral density T scores between -1 and -2.5 and/or other clinical risk factors for osteoporosis were enrolled in a 24-month, phase 3, randomized, double-blind, placebo- and active-controlled trial. They received daily treatment with bazedoxifene 10, 20, or 40 mg; placebo; or raloxifene 60 mg. Reproductive safety assessments included periodic transvaginal ultrasound measurements of endometrial thickness, ovarian volume, and presence of ovarian cysts; periodic endometrial biopsies; and adverse event reporting. RESULTS: Bazedoxifene was not associated with a significant change from baseline in mean endometrial thickness at month 24. The percentage of participants with a change from baseline in endometrial thickness or endometrial thickness greater than 5 mm at month 24 was similar among groups. There was no consensus diagnosis of endometrial hyperplasia or malignancy in the bazedoxifene or raloxifene groups; the rates of other histologic findings, including endometrial polyps, were low (<5%) and similar among groups. No significant between-group differences were found in the change from baseline in ovarian volume, number or size of ovarian cysts, or incidence of ovarian cancer. Reports of breast pain (<4%) and breast cancer (<1%) were low and evenly distributed among groups. CONCLUSION: A favorable endometrial, ovarian, and breast safety profile was found after 2 years of treatment with bazedoxifene in healthy, recently postmenopausal women at risk for osteoporosis.
Asunto(s)
Mama/efectos de los fármacos , Endometrio/efectos de los fármacos , Indoles/efectos adversos , Osteoporosis Posmenopáusica/prevención & control , Ovario/efectos de los fármacos , Moduladores Selectivos de los Receptores de Estrógeno/efectos adversos , Densidad Ósea , Neoplasias de la Mama/inducido químicamente , Neoplasias de la Mama/epidemiología , Método Doble Ciego , Hiperplasia Endometrial/inducido químicamente , Hiperplasia Endometrial/epidemiología , Neoplasias Endometriales/inducido químicamente , Neoplasias Endometriales/epidemiología , Endometrio/diagnóstico por imagen , Femenino , Humanos , Indoles/administración & dosificación , Persona de Mediana Edad , Quistes Ováricos/inducido químicamente , Quistes Ováricos/epidemiología , Neoplasias Ováricas/inducido químicamente , Neoplasias Ováricas/epidemiología , Ovario/diagnóstico por imagen , Placebos , Posmenopausia , Factores de Riesgo , UltrasonografíaRESUMEN
OBJECTIVE: The aim of this study was to evaluate the endometrial, ovarian, and breast safety of bazedoxifene used as a treatment for postmenopausal osteoporosis. METHODS: Healthy women (aged 55-85 y) with osteoporosis were enrolled in a randomized, double-blind, placebo-controlled phase 3 trial. Participants were randomized to treatment with bazedoxifene 20 or 40 mg, raloxifene 60 mg, or placebo daily for 3 years. Endometrial and ovarian safety was assessed by periodic transvaginal ultrasonography and endometrial biopsy through 24 months. Gynecologic and breast-related adverse events were recorded throughout the study. RESULTS: Among 753 participants with available transvaginal ultrasonography data, there were no significant between-group differences in overall endometrial thickness or in the percentage of participants with endometrial thickness greater than 5 mm at 12 or 24 months. Changes in the mean endometrial thickness (+/-SE) from baseline were -0.07 +/- 0.11 mm (bazedoxifene 20 mg), 0.10 +/- 0.11 mm (bazedoxifene 40 mg), 0.16 +/- 0.12 mm (raloxifene 60 mg), and -0.08 +/- 0.11 mm (placebo) at 24 months. There was one report of endometrial hyperplasia in each group, and there were zero, two, two, and three reports of endometrial carcinoma with bazedoxifene 20 and 40 mg, raloxifene 60 mg, and placebo, respectively. There were no clinically important changes from baseline in the number or size of ovarian cysts among groups. There was a significantly lower incidence of fibrocystic breast disease (P Asunto(s)
Mama/efectos de los fármacos
, Endometrio/efectos de los fármacos
, Indoles/administración & dosificación
, Osteoporosis Posmenopáusica/tratamiento farmacológico
, Ovario/efectos de los fármacos
, Moduladores Selectivos de los Receptores de Estrógeno/administración & dosificación
, Anciano
, Anciano de 80 o más Años
, Biopsia
, Quiste Mamario/epidemiología
, Neoplasias de la Mama/epidemiología
, Método Doble Ciego
, Hiperplasia Endometrial/epidemiología
, Neoplasias Endometriales/epidemiología
, Endometrio/diagnóstico por imagen
, Endometrio/patología
, Femenino
, Enfermedad Fibroquística de la Mama/epidemiología
, Humanos
, Indoles/efectos adversos
, Persona de Mediana Edad
, Ovario/diagnóstico por imagen
, Placebos
, Moduladores Selectivos de los Receptores de Estrógeno/efectos adversos
, Ultrasonografía
RESUMEN
OBJECTIVE: To determine the utility of screening for depression in pregnant women with human immunodeficiency virus (HIV) infection. STUDY DESIGN: Women with HIV infection who received prenatal care at an inner-city institution between March 2004 and March 2006 were offered the Beck Depression Inventory (BDI), a screening tool to detect depressive symptomatology. Scores >9 were considered positive. RESULTS: Of 51 subjects who participated, 53% had positive screening scores for depression. Of those whose scores were positive, 33% had no prior history of psychiatric illness. Those in whom HIV was diagnosed during pregnancy had higher mean and median BDI scores than those with HIV diagnosed before pregnancy (21.2 vs. 13.3 and 21 vs. 9.5, respectively; p = 0.049). Two factors were associated with positive screenings: history of psychiatric disease (p = 0.001) and history of substance abuse (p = 0.042). Patients with positive screenings first presented for prenatal care at a later gestational age and had fewer prenatal visits than those without evidence of depression (14.9 vs. 12.0, p = 0.035 and 9.2 vs. 11.3, p = 0.045). More than half (56%) who screened positive received psychological care during the prenatal period. CONCLUSION: Women with HIV infection should routinely be screened for depression during pregnancy. Those with positive screens should be offered formal psychological evaluation.
Asunto(s)
Trastorno Depresivo/diagnóstico , Trastorno Depresivo/epidemiología , Infecciones por VIH/psicología , Complicaciones Infecciosas del Embarazo/psicología , Diagnóstico Prenatal , Adolescente , Adulto , Estudios de Cohortes , Femenino , Humanos , Tamizaje Masivo , Evaluación de Necesidades , Embarazo , Prevalencia , Pruebas Psicológicas , Factores de RiesgoRESUMEN
UNLABELLED: Osteoporosis is an increasingly common health concern in postmenopausal women. In a 2-yr phase III study, bazedoxifene prevented bone loss, reduced bone turnover, and was well tolerated in early postmenopausal women with normal or low BMD. INTRODUCTION: Bazedoxifene is a novel selective estrogen receptor modulator that has increased BMD and bone strength in experimental models, without stimulating breast or uterus. This 24-mo, randomized, double-blind study assessed the efficacy and safety of three doses of bazedoxifene compared with placebo and raloxifene in the prevention of postmenopausal osteoporosis. MATERIALS AND METHODS: Healthy postmenopausal women with a BMD T-score at the lumbar spine or femoral neck between -1.0 and -2.5 or clinical risk factors for osteoporosis were randomly assigned to one of five groups: bazedoxifene 10, 20, or 40 mg/d, placebo, or raloxifene 60 mg/d. All women received elemental calcium. Efficacy outcomes included changes from baseline through 24 mo in BMD of the lumbar spine, hip, femoral neck, and femoral trochanter and biomarkers of bone metabolism. RESULTS: The intent-to-treat population included 1434 women (mean age, 58 yr; mean time from last menstrual period, 11 yr). All doses of bazedoxifene and raloxifene prevented bone loss, whereas in the placebo group, there was significant loss of BMD at all skeletal sites. Mean differences in percent change in lumbar spine BMD from baseline to 24 mo relative to placebo were 1.08 +/- 0.28%, 1.41 +/- 0.28%, 1.49 +/- 0.28%, and 1.49 +/- 0.28% for 10, 20, and 40 mg bazedoxifene and 60 mg raloxifene, respectively (p < 0.001 for all comparisons). Comparable BMD responses were observed at other body sites. Significant and comparable decreases in serum osteocalcin and C-telopeptide levels from baseline and relative to placebo with active treatment were observed as early as 3 mo and were sustained through study conclusion (p < 0.001). Overall incidences of adverse events, serious adverse events, and discontinuations caused by adverse events were similar between groups. The most common adverse events included headache, infection, arthralgia, pain, hot flush, and back pain. CONCLUSIONS: Treatment with bazedoxifene prevented bone loss and reduced bone turnover equally as well as raloxifene and was generally well tolerated in postmenopausal women with normal/low BMD.
Asunto(s)
Densidad Ósea/efectos de los fármacos , Remodelación Ósea/efectos de los fármacos , Posmenopausia , Clorhidrato de Raloxifeno/farmacología , Moduladores Selectivos de los Receptores de Estrógeno/farmacología , Método Doble Ciego , Femenino , Humanos , Persona de Mediana Edad , PlacebosRESUMEN
BACKGROUND: Long-term survival of patients with congenital human immunodeficiency virus (HIV) infection has resulted in a growing cohort of perinatally infected adolescents and young adults who are sexually active and becoming pregnant. CASES: Two cases are presented to report our management of pregnancies resulting from unprotected sexual practices in perinatally HIV-infected adolescents who were HIV serodiscordant. An integrated approach, involving the specialties of pediatrics, obstetrics and gynecology, and infectious disease, along with social services, was used to provide comprehensive care to these patients. CONCLUSION: There is a need to address reproductive health issues, especially risky sexual behaviors, in adolescents who are HIV infected.
Asunto(s)
Infecciones por VIH/transmisión , Complicaciones Infecciosas del Embarazo/virología , Sexo Inseguro , Adolescente , Servicios de Salud del Adolescente , Femenino , Humanos , Transmisión Vertical de Enfermedad Infecciosa , Planificación de Atención al Paciente , Grupo de Atención al Paciente , Embarazo , Embarazo en Adolescencia , Servicio SocialRESUMEN
Although perinatal HIV prophylaxis is probably the most successful HIV prevention intervention to date, between 280 and 370 HIV-positive infants are born in the United States each year. A major reason for continuing vertical transmission is that some HIV-infected women are not aware of their positive HIV serostatus before delivery. A rapid HIV testing program was developed and implemented in a labor and delivery suite at an inner-city teaching hospital in a nonresearch setting. Between April 2002 and June 2005, 259 rapid HIV tests were performed. For the first 19 months of the study, the expedited enzyme-linked immunosorbent assay (ELISA) was performed in 62 patients. For the remainder of the study, the OraQuick rapid HIV-1 antibody test was performed in 197 patients. Turnaround times for the ELISA and OraQuick test were 262 minutes and 143 minutes, respectively, a significant difference (P = .002). Four women had positive test results. Voluntary rapid HIV testing is a feasible strategy for detection of HIV seropositivity in pregnant patients who present in a labor and delivery suite with unknown serostatus. This provides an opportunity to administer antiretroviral prophylaxis and to incorporate other obstetric interventions to decrease vertical HIV transmission.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Parto Obstétrico , Infecciones por VIH/diagnóstico , Trabajo de Parto , Complicaciones Infecciosas del Embarazo/diagnóstico , Zidovudina/uso terapéutico , Algoritmos , Fármacos Anti-VIH/administración & dosificación , Esquema de Medicación , Ensayo de Inmunoadsorción Enzimática , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/transmisión , VIH-1 , Hospitales de Enseñanza , Humanos , Recién Nacido , Transmisión Vertical de Enfermedad Infecciosa , Embarazo , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Factores de Tiempo , Estados Unidos , Población Urbana , Zidovudina/administración & dosificaciónRESUMEN
Owing to advances in the understanding and treatment of HIV infection, most persons infected with HIV are now living longer, healthier lives. With the dramatic reduction in mother-to-child transmission in the past decade, the outlook on life has changed for women with HIV infection. It is critical that a new strategic plan for prevention of HIV transmission and a proactive approach to reproductive health care be implemented by health care providers who care for these women. Promotion of risk reduction counseling, screening for sexually transmitted diseases and lower genital tract disease, assessment of options for birth control, and pre-conception counseling should be integral components of gynecologic health care for HIV-infected women. This article reviews the current status of gynecologic and reproductive health care for HIV-infected women.
Asunto(s)
Terapia Antirretroviral Altamente Activa , Anticoncepción/métodos , Servicios de Planificación Familiar , Infecciones por VIH , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Enfermedades de Transmisión Sexual/prevención & control , Adulto , Consejo , Interacciones Farmacológicas , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/prevención & control , Infecciones por VIH/transmisión , Humanos , Embarazo , Enfermedades de Transmisión Sexual/diagnósticoRESUMEN
PURPOSE: To determine the effect of increasing the aerobic component of the school's physical activity program and improving the knowledge about weight control and blood pressure on the blood pressure and body fat of early adolescents. METHODS: The subjects were 1140 youth aged 11 to 14 years (630 females, 510 males; 64% white, 24.4% African-American, and 11.6% "other"), who were randomly assigned by school into four treatment groups: exercise only, education only, exercise and education combined, and control group. Heights, weights, and skinfold thicknesses were measured, and body mass index (BMI) was computed kg/m(2). Blood pressure was obtained in duplicate using a random-zero mercury sphygmomanometer. Maximal oxygen uptake was predicted from a submaximal cycle ergometer test. Data were analyzed using analysis of covariance statistics, adjusting for gender, ethnicity, age, socioeconomic status, and initial baseline characteristics. RESULTS: Systolic and diastolic blood pressures increased more in the control group than in the intervention groups (p =.001). The BMI did not change significantly (p =.709), but the sum of skinfolds increased less in subjects in the exercise intervention groups than the education only or control groups (p =.0001). The small increase in (p)VO(2)max of the combined exercise and education group was significantly greater than the education only group (p =.0001). CONCLUSION: An exercise program for youth can have a positive effect on blood pressure independent of body weight loss.
Asunto(s)
Presión Sanguínea , Enfermedades Cardiovasculares/prevención & control , Ejercicio Físico/fisiología , Promoción de la Salud/métodos , Educación y Entrenamiento Físico , Servicios de Salud Escolar/organización & administración , Pérdida de Peso , Adolescente , Índice de Masa Corporal , Niño , Femenino , Humanos , Masculino , North Carolina , Grosor de los Pliegues CutáneosRESUMEN
BACKGROUND: Sciatic nerve compression has been well documented as a cause of perioperative sciatic neuropathy but rarely during cesarean. CASE: A parturient complained of left foot drop after cesarean delivery for twins performed under spinal anesthesia. Intraoperatively, her right hip was raised with padding under the right buttock to tilt the pelvis approximately 30 degrees to the left. Postoperatively, the patient had weakness, sensory changes, and diminished reflexes in the left lower extremity. Electrodiagnostic studies supported a diagnosis of neurapraxia and partial denervation in the distribution of the sciatic nerve. By postpartum week 6, she had full recovery. CONCLUSION: Elevating the right buttock during cesarean can cause compression of the underlying structures of the left buttock and result in sciatic neuropathy. Decreasing the duration of time the patient is in the left lateral position may reduce the risk of this uncommon but debilitating complication.